PT  - JOURNAL ARTICLE
AU  - Cui, Naiyuan
AU  - Li, Haiwei
AU  - Sun, Weiping
AU  - Wang, Zefeng
AU  - Yuan, Zhongyu
AU  - Zhu, Botao
AU  - Liu, Yutong
AU  - Liu, Huanfu
AU  - Wu, Yongquan
AU  - Zhang, Xiaoping
TI  - Clinical utility of the 4S-AF scheme in predicting recurrence of atrial fibrillation after radiofrequency catheter ablation
AID  - 10.1101/2024.07.02.24309867
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.02.24309867
4099  - http://medrxiv.org/content/early/2024/07/03/2024.07.02.24309867.short
4100  - http://medrxiv.org/content/early/2024/07/03/2024.07.02.24309867.full
AB  - Background The 4S-AF scheme, consisting of four domains related to atrial fibrillation (AF) [stroke risk (St), symptoms (Sy), severity of AF burden (Sb), and substrate (Su)], represents a novel approach for the structural characterization of AF. We aimed to assess the clinical utility of the scheme in predicting AF recurrence after radiofrequency catheter ablation (RFCA).Methods We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds.Results Of 345 patients [age 61 (IQR: 53-68) years, 34.2% female, 70.7% paroxysmal AF] were analyzed. The median duration of AF history was 12 (IQR: 3-36) months, and the median number of comorbidities was 2 (IQR: 1-3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13-37) months, AF recurrence occurred in 34.4% of patients. Both 4S-AF scheme score (HR 1.38, 95% CI: 1.19–1.59, P<0.001) and 2S-AF scheme by eliminating the Sy and St domains (HR 1.59, 95% CI: 1.33–1.89, P<0.001) were independent predictors of AF recurrence after RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25–2.72, P=0.002) and Su (HR 1.71, 95% CI: 1.36–2.14, P<0.001). Furthermore, 4S-AF scheme score (AUC 65.2%, 95% CI: 59.3–71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2–had a modest ability to predict AF recurrence after RFCA.Conclusions The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA and aids us in identifying patients with a high risk of AF recurrence after RFCA.What Is New?The 4S-AF scheme can be used to characterize and assess patients with atrial fibrillation (AF) who will undergo radiofrequency catheter ablation (RFCA).A higher 4S-AF scheme score and 2S-AF scheme score modified by eliminating the Sy and St domains of the 4S-AF scheme score were significantly associated with an elevated atrial fibrillation (AF) recurrence rate after RFCA.Severity of AF burden (Sb) and substrate (Su) domain scores were independently associated with AF recurrence outcomes after RFCA.4S-AF scheme score and 2S-AF scheme score had modest predictive capability for AF recurrence.What Are the Clinical Implications?AF is a common cardiac arrhythmia and recurrence rates of AF after RFCA are substantial.Using the 4S-AF scheme to characterize AF may aid in identifying high-risk patients who need to receive RFCA in terms of AF recurrence.Compared to existing risk stratification methods, such as HATCH and CHA2DS2-VASc score, 4S-AF scheme score and 2S-AF scheme score had better clinical predictive capability of AF recurrence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by National Natural Science Foundation of China (Grant No. 81500365), Beijing Natural Science Foundation (Grant No. 7172040), Beijing JST Research Funding (Grant No. ZR-202212), and Capital Medical University Major Science and Technology Innovation Research and Development Special Fund (Grant No. KCZD202201).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was designed and performed in accordance with the Declaration of Helsinki for Human Research and was approved by the Beijing Anzhen Hospital Ethics Committee (Approval No: 2024103X).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes